Burning Mouth Syndrome Treated with Low-Level Laser and Clonazepam: A Randomized, Single-Blind Clinical Trial.

Objective: Burning mouth syndrome (BMS) is a chronic pain disorder characterized by intraoral burning or dysaesthetic sensation, with the absence of any identifiable lesions. Numerous treatments for BMS have been investigated, though without conclusive results. An analysis was conducted of the efficacy of treatment with a low-level diode laser and clonazepam in patients with BMS, and a study was carried out on the levels of different salivary biomarkers before and after treatment.

Material And Methods: A randomized, single-blind clinical trial was carried out involving 89 patients divided into the following groups: group 1 (laser, The Helbo Theralite Laser 3D Pocket Probe + clonazepam) (n = 20), group 2 (sham laser placebo) (n = 19), group 3 (laser) (n = 21) and group 4 (clonazepam) (n = 18). Symptom intensity was scored based on a visual analogue scale (VAS). Sialometry was performed before and after treatment, and the Xerostomia Inventory, Oral Health Impact Profile-14 (OHIP-14) and Mini-Nutritional Assessment (MNA) questionnaires were administered. The following markers were measured in saliva samples: interleukins (IL2, IL4, IL5, IL6, IL7, IL8, IL1β, IL10, IL12, IL13, IL17, IL21 and IL23), proteins (MIP-3α, MIP-1α and MIP-1β), GM-CSF, interferon gamma (IFNγ), interferon-inducible T-cell alpha chemoattractant (ITAC), fractalkine and tumor necrosis factor α (TNFα).

Results: A significant decrease in the VAS scores was observed after treatment in group 1 (laser + clonazepam) ( = 0.029) and group 3 (laser) ( = 0.005). In turn, group 3 (laser) showed a decrease in the salivary concentration of fractalkine ( = 0.025); interleukins IL12 ( = 0.048), IL17 ( = 0.020), IL21 ( = 0.008), IL7 ( = 0.001) and IL8 ( = 0.007); proteins MIP1α ( = 0.048) and MIP1β ( = 0.047); and TNFα ( = 0.047) versus baseline. Following treatment, group 1 (laser + clonazepam) showed significant differences in IL21 ( = 0.045) and IL7 ( = 0.009) versus baseline, while group 4 (clonazepam) showed significant differences in IL13 ( = 0.036), IL2 ( = 0.020) and IL4 ( = 0.001). No significant differences were recorded in group 2 (sham laser placebo).

Conclusions: The low-level diode laser is a good treatment option in BMS, resulting in a decrease in patient symptoms and in salivary biomarkers. However, standardization of the intervention protocols and laser intensity parameters is needed in order to draw more firm conclusions.